Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 600mg - injection with diluent - 600 mg - active: rifampicin 600mg excipient: sodium formaldehydesulfoxylate sodium hydroxide water for injection polysorbate 80 water for injection - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - isoniazid 100mg; rifampicin 150mg - tablet - active: isoniazid 100mg rifampicin 150mg excipient: acacia calcium stearate carmellose sodium carnauba wax colloidal silicon dioxide colophony erythrosine gelatin hard paraffin kaolin magnesium carbonate magnesium stearate microcrystalline cellulose povidone purified talc sodium laurilsulfate sucrose titanium dioxide white beeswax - treatment of all forms of tuberculosis.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - isoniazid 150mg; rifampicin 300mg - tablet - active: isoniazid 150mg rifampicin 300mg excipient: acacia calcium stearate carmellose sodium carnauba wax colloidal silicon dioxide colophony gelatin hard paraffin kaolin magnesium carbonate magnesium stearate microcrystalline cellulose povidone purified talc sodium laurilsulfate sucrose sunset yellow aluminium lake titanium dioxide white beeswax - treatment of all forms of tuberculosis.

Israel - englanti - Ministry of Health

j-c health care ltd - etravirine - tablets - etravirine 100 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti) - containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - digoxin - tablet - 250 microgram(s) - digitalis glycosides; digoxin

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - digoxin - oral solution - 50 microgram(s)/millilitre - digitalis glycosides; digoxin

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - digoxin - tablet - 62.5 microgram(s) - digitalis glycosides; digoxin

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - digoxin - solution for injection - 0.25 percent volume/volume - digitalis glycosides; digoxin

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

laboratoires serb - primidone - tablet - 250 milligram(s) - barbiturates and derivatives; primidone

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin - capsule, hard - 150 milligram(s) - antibiotics; rifampicin